查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1832202

抗凝血剂市场（按药物类别、给药途径、适应症、最终用户和分销管道划分）—2025-2032 年全球预测

Anticoagulants Market by Drug Class, Route Of Administration, Indication, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，抗凝血剂市场将成长至 979.2 亿美元，复合年增长率为 10.44%。

主要市场统计数据
基准年2024年 442.4亿美元
预计2025年 489.2亿美元
预测年份：2032年 979.2亿美元
复合年增长率（%） 10.44%

定义现代抗凝血治疗和市场互动的临床驱动因素、市场挑战和商业动态的简明框架

抗凝血治疗处于急性护理、慢性病管理和预防医学的交叉领域，影响循环系统、血管外科和全科医学的治疗方法结果。临床医生、付款人和医疗服务提供者已经经历了一个药物快速创新、初级保健途径转变以及对安全性、依从性和便利性期望不断提升的时代。本介绍将重点介绍决定治疗选择的临床因素、影响药物可近性的物流限制以及影响产品到达患者途径的商业性动态，从而提供背景资讯。

近年来，治疗方案组合发生了变化，口服直接抗凝血剂与成熟的肠外给药方案一起逐渐普及，而新的作用机转也正在后期临床试验中涌现。采用模式因适应症和护理环境而异，门诊和居家照护管理在支付方和提供者的策略中变得越来越重要。对供应链漏洞、原材料采购和生产品质的监管审查为商业风险和业务规划增添了新的维度。本节概述了临床需求、医疗保健服务模式和法律规范如何融合，为製造商、卫生系统和分销合作伙伴带来短期压力和长期机会，为后续分析提供了重要背景。

临床有效性、安全性和给药便利性之间的相互作用是整份报告评估的主要观点。引言部分将讨论锚定在现实世界的医疗保健途径和采购现实中，为读者解读后续的细分洞察、区域差异和企业策略奠定了基础。

临床创新、分散式照护模式和弹性供应策略如何重塑抗凝血治疗的治疗方法方案和商业性定位

抗凝血药物领域正在经历变革性变革，其驱动力包括作用机制的创新、医疗服务模式的转变以及对以患者为中心的治疗结果的日益重视。口服直接抗凝血药物重新定义了门诊心房颤动和静脉血栓栓塞症的预防管理，减轻了监测负担，并重塑了处方规范。同时，针对因子XI和其他新型凝血途径的药物的后期研究有望带来具有差异化安全性的治疗方法，这可能会进一步调整临床指南和支付方的核保决策。

同时，医疗保健服务模式也在不断发展。门诊手术中心和居家医疗管理的扩张，加上数位化依从性工具和远端医疗通讯协定的出现，正在将需求从住院环境转向分散式照护。地缘政治紧张局势和疫情时期的干扰加速了供应链现代化和多元化的进程，促使製造商重新评估筹资策略并投资裁员。付款方的优先事项越来越强调基于价值的合约和真实世界证据，这激励製造商展示超出随机对照试验范围的疗效。

综合起来，这些因素共同创造了一个更分散但机会丰富的环境。将临床创新与扩充性解决方案和弹性供应链相结合的公司，将占据新的医疗途径，而未能适应的相关人员则面临利润压缩和处方流失的风险。最终结果是，竞争环境更加动态，临床差异化、患者便利性和营运敏捷性将决定长期成功。

评估关税主导的供应链转变和战略应对措施的系统性后果，这些措施重新定义了2025年的采购和营运弹性

2025年颁布的政策措施为美国医疗保健生态系统中的製造商、经销商和供应商带来了一系列新的变数。这些关税调整的累积效应增加了跨国采购活性药物原料药和成品的成本和复杂性，给采购链带来了压力，并加速了供应商关係的策略转变。依赖单一来源供应商和精益库存模式的公司面临直接的营运挑战，迫使它们重新竞标、延长前置作业时间或寻求其他供应途径。

为因应这项挑战，市场参与企业采取了各种风险规避策略。一些製造商加速了关键原材料的垂直整合或近岸外包，而另一些製造商则透过与多家供应商签订多年合约来确保业务的连续性。经销商和大型医疗系统扩大了战略库存，并优先与能够提供透明可追溯性和品质保证的製造商合作。支付者和医院处方委员会为应对成本压力，加强了对比较效益和总医疗成本的审查，从而影响了谈判动态和报销模式。

关税造成了短期和中期摩擦，但也引发了系统性变革。这次事件刺激了对国内製造能力的投资，并更加重视供应链韧性作为竞争策略的核心要素。展望未来，能够将关税风险纳入采购模式并实施灵活采购的相关人员将更有能力保持供应的连续性，并为临床医生和患者保留治疗选择。

细分主导框架，将药物类别、给药途径、临床适应症、医疗保健环境和分销管道与策略重点联繫起来

细分提供了必要的分析立足点，有助于将临床和商业性动态转化为跨药物类别、给药途径、适应症、最终用户和分销管道的可行洞察。在药物类别中，研究对象包括直接口服抗凝血剂、低分子量肝素、未分级肝素和维生素K拮抗剂，每种药物都有不同的药理特性、监测需求和影响处方行为的临床作用。直接口服抗凝血剂减少了对常规实验室监测的依赖，并实现了门诊治疗途径，而低分子量肝素和未分级肝素在手术全期护理和某些高风险族群中至关重要。维生素K拮抗剂在新药存在成本和临床禁忌症的情况下仍发挥重要作用。

目录

第一章 引言

第二章分析方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 扩展远端患者监护技术，实现个人化抗凝血治疗剂量指导
  • 生技新兴企业公司与知名製药公司进行策略合作，加速新型 XI 因子抑制剂的测试
  • 真实世界证据在新型抗凝血剂核准申请的新用途
  • 整合人工智慧演算法预测抗凝血处方中的个别出血风险
  • 增加低剂量利伐沙班用于高风险病患术后静脉血栓栓塞症预防的说明书仿单标示外
  • 转向以患者为中心的数位依从性工具可改善直接口服抗凝血剂的依从性和疗效
  • 主要市场专利悬崖之后 Xa 因子抑制剂非专利药的市场进入趋势

第六章：美国关税的累积影响（2025年）

第七章：人工智慧（AI）的累积影响（2025年）

8. 抗凝血剂市场（依药物类别）

  • 直接口服抗凝血药
  • 低分子量肝素
  • 未分级肝素
  • 维生素K拮抗剂

9. 抗凝血剂市场（依给药途径）

  • 注射
    • 静脉
    • 皮下
  • 口服

第 10 章抗凝血剂市场（按适应症）

  • 心房颤动
  • 深层静脉栓塞症
  • 肺动脉栓塞
  • 预防静脉血栓栓塞症

第 11 章。抗凝血剂市场（按最终用户划分）

  • 门诊手术中心
  • 诊所
  • 居家医疗
  • 医院

第 12 章。抗凝剂市场（按分销管道）

  • 离线
  • 网路药局

第十三章 抗凝血剂市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章 抗凝血剂市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。各国抗凝血剂市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 市占率分析（2024年）
  • FPNV定位矩阵（2024年）
  • 竞争分析
    • Johnson & Johnson
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company, Limited
    • Sanofi SA
    • Pfizer Inc.
    • Abbott Laboratories
    • Amgen Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Lupin Limited
    • Cipla Limited
Product Code: MRR-4358BACA80B8

The Anticoagulants Market is projected to grow by USD 97.92 billion at a CAGR of 10.44% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 44.24 billion
Estimated Year [2025] USD 48.92 billion
Forecast Year [2032] USD 97.92 billion
CAGR (%) 10.44%

A concise framing of clinical drivers, delivery challenges, and commercial dynamics that define contemporary anticoagulant therapy and market interactions

Anticoagulant therapy lies at the intersection of acute care, chronic disease management and preventative medicine, shaping outcomes across cardiology, vascular surgery and general medicine. Clinicians, payers and providers have navigated an era of rapid pharmacologic innovation, shifting primary care pathways, and evolving expectations for safety, adherence and convenience. This introduction frames the current landscape by clarifying the clinical drivers that determine therapy selection, the logistical constraints that shape availability, and the commercial dynamics that influence how products reach patients.

In recent years, the therapeutic mix has changed as oral direct anticoagulants gained traction alongside established parenteral agents, while novel mechanisms of action emerge from late-stage clinical trials. Adoption patterns vary by indication and care setting, with ambulatory and homecare administration increasingly central to payer and provider strategies. Supply chain vulnerabilities, raw material sourcing, and regulatory scrutiny of manufacturing quality have added new dimensions to commercial risk and operational planning. This section sets out the critical context for subsequent analysis, outlining how clinical need, delivery models and regulatory frameworks converge to create both near-term pressures and long-term opportunities for manufacturers, health systems and distribution partners.

Throughout the report, the interplay between clinical efficacy, safety profiles and delivery convenience will serve as the primary lens for assessment. By anchoring discussion in real-world care pathways and procurement realities, the introduction prepares readers to interpret segmentation insights, regional nuances and corporate strategies that follow.

How clinical innovation, decentralized care models, and resilient supply strategies are jointly reshaping therapy choices and commercial positioning in anticoagulant care

The anticoagulant landscape is undergoing transformative shifts driven by innovation in mechanism of action, changes in care delivery, and intensified focus on patient-centric outcomes. Oral direct anticoagulants have redefined outpatient management of atrial fibrillation and venous thromboembolism prevention, reducing monitoring burdens and reshaping prescribing norms. Meanwhile, late-stage research into agents targeting factor XI and other novel coagulation pathways promises therapies with differentiated safety profiles that could further recalibrate clinical guidelines and payer coverage decisions.

Concurrently, delivery models are evolving. The expansion of ambulatory surgical centers and homecare administration, combined with digital adherence tools and telehealth follow-up protocols, is shifting demand away from inpatient settings and toward decentralized care. Supply chain modernization and diversification efforts-accelerated by geopolitical tensions and pandemic-era disruptions-are prompting manufacturers to reassess sourcing strategies and invest in redundancies. Payer priorities increasingly emphasize value-based contracting and real-world evidence, incentivizing manufacturers to demonstrate outcomes beyond randomized controlled trials.

Taken together, these forces create a more fragmented yet opportunity-rich environment. Companies that integrate clinical innovation with scalable delivery solutions and resilient supply chains are positioned to capture new care pathways, while stakeholders who fail to adapt risk margin compression and formulary displacement. The net effect is a more dynamic competitive arena in which clinical differentiation, patient convenience and operational agility determine long-term success.

Assessing the systemic consequences of tariff-driven supply chain shifts and strategic responses that have redefined procurement and operational resilience in 2025

Policy measures enacted in 2025 introduced a new set of variables for manufacturers, distributors and providers operating in the United States healthcare ecosystem. The cumulative effect of those tariff adjustments has been to increase the cost and complexity of cross-border sourcing for active pharmaceutical ingredients and finished formulations, creating pressure along the procurement chain and accelerating strategic shifts in supplier relationships. Firms reliant on single-source suppliers or lean inventory models confronted immediate operational challenges and were forced to reprice bids, extend lead times or pursue alternative supply routes.

In response, market participants employed a combination of risk mitigation strategies. Some manufacturers accelerated vertical integration and nearshoring initiatives for critical raw materials, while others secured multi-year contracts with diversified suppliers to lock in continuity. Distributors and large health systems expanded their strategic inventories and prioritized partnerships with manufacturers that demonstrated transparent traceability and quality assurances. Payers and hospital formulary committees, reacting to cost pressures, intensified scrutiny of comparative effectiveness and total cost of care, which in turn influenced negotiation dynamics and reimbursement patterns.

While tariffs introduced short-to-medium-term friction, they also catalyzed systemic change. The episode precipitated investment in domestic manufacturing capacity and heightened attention to supply chain resilience as a core element of competitive strategy. Going forward, stakeholders who integrate tariff risk into procurement models and who can operationalize flexible sourcing will be better positioned to sustain supply continuity and preserve therapeutic choice for clinicians and patients.

A segmentation-driven framework linking drug class, administration routes, clinical indications, care settings, and distribution channels to strategic priorities

Segmentation provides the analytical scaffolding needed to translate clinical and commercial dynamics into actionable insight across drug classes, routes of administration, indications, end users and distribution channels. Based on Drug Class, the market is studied across Direct Oral Anticoagulants, Low Molecular Weight Heparin, Unfractionated Heparin, and Vitamin K Antagonists, each of which has distinct pharmacologic profiles, monitoring requirements and clinical roles that influence prescribing behavior. Direct oral anticoagulants have reduced the dependence on routine laboratory monitoring and enabled outpatient pathways, whereas low molecular weight heparin and unfractionated heparin remain indispensable in perioperative care and in specific high-risk populations. Vitamin K antagonists continue to have a role where cost considerations or clinical contraindications to newer agents apply.

Based on Route Of Administration, the market is studied across Injectable and Oral. The Injectable is further studied across Intravenous and Subcutaneous, reflecting the operational differences encountered in hospitals, ambulatory surgical centers and homecare settings where training, cold-chain logistics and administration frequency shape adoption. Based on Indication, the market is studied across Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, and Venous Thromboembolism Prevention, with each indication imposing unique efficacy and safety tradeoffs that inform guideline recommendations and payer coverage. Based on End User, the market is studied across Ambulatory Surgical Centers, Clinics, Homecare Settings, and Hospitals, a segmentation that highlights how site-of-care economics, staffing models and care pathways determine product selection and commercial strategy. Based on Distribution Channel, the market is studied across Offline and Online Pharmacy, recognizing the growing role of e-commerce and specialty pharmacy services in enabling home administration and improved adherence.

This segmentation-based lens allows stakeholders to map clinical needs to operational constraints and to design product, pricing and access strategies that reflect real-world use cases. By integrating segmentation signals with clinical outcomes and supply considerations, companies can prioritize investments where clinical differentiation aligns with sustainable commercial opportunity.

Regional dynamics shaping access, reimbursement and delivery across the Americas, Europe Middle East and Africa, and Asia-Pacific with distinct operational imperatives

Regional dynamics materially influence how anticoagulant therapies are accessed, reimbursed and administered, giving rise to differentiated commercial and clinical priorities across geographies. In the Americas, healthcare systems exhibit a strong emphasis on innovation adoption in outpatient care, with payers increasingly leveraging outcomes data to inform formulary decisions and value-based arrangements. The prevalence of ambulatory surgical centers and robust homecare programs in many markets accelerates uptake of oral therapies and subcutaneous options, while regulatory oversight and supply chain resilience remain central concerns for procurement teams.

In Europe, Middle East & Africa, heterogeneity across national health systems drives a patchwork of adoption patterns. Some markets prioritize budgetary control and cost-effectiveness analyses that favor established generics and biosimilars, whereas others pursue rapid uptake of novel agents supported by centralized reimbursement decisions or specialist-led care pathways. Regional differences in manufacturing capacity and raw material sourcing also influence supply chain risk profiles, and in several countries there is expanded interest in decentralized care and digital adherence programs to improve outpatient management.

In the Asia-Pacific region, the landscape is shaped by a mix of rapidly modernizing healthcare infrastructure and enduring access constraints. Public procurement strategies, local manufacturing initiatives, and growing private sector investment are driving both broader access and competitive pressures. Regional regulators are increasingly receptive to real-world evidence and adaptive approval pathways, which creates opportunities for differentiated products to establish clinical value. Across all regions, cross-border supply reliability, local clinical practice norms, and payer mechanisms remain pivotal in determining how therapies are prioritized and delivered.

How incumbent innovators, generics manufacturers, and clinical-stage entrants are competing on evidence generation, supply reliability, and integrated commercial offerings

Competitive dynamics within the anticoagulant sector reflect a mixture of entrenched global players, agile generics manufacturers and innovative clinical-stage entrants. Established pharmaceutical companies that developed the first wave of direct oral anticoagulants continue to defend market position through lifecycle management, clinical evidence generation and partnerships that expand access. Generic and biosimilar manufacturers are exerting downward pricing pressure in segments where patents have expired, while increasing manufacturing scale to meet demand in hospital and outpatient channels.

New entrants and clinical-stage programs targeting factor XI and related pathways represent a potential inflection point in the therapeutic mix, creating a runway for differentiated safety claims and novel positioning in populations at high bleeding risk. Commercial success for these agents will depend not only on trial outcomes but also on payer willingness to reimburse based on comparative effectiveness and real-world performance. Meanwhile, contract manufacturers and regional producers play a strategic role in ensuring supply continuity, prompting larger firms to secure long-term manufacturing partnerships.

Across the competitive landscape, companies that combine robust clinical evidence, clear value propositions for payers, and operational commitments to supply reliability will gain strategic advantage. Tactical moves such as targeted acquisitions, co-promotion agreements, and investments in digital adherence solutions are shaping the industry's competitive contours, as firms seek integrated offerings that address clinician needs and patient convenience simultaneously.

Actionable and pragmatic strategies for manufacturers and providers to strengthen clinical positioning, secure supply resilience, and demonstrate payer-relevant value

Industry leaders should adopt a multi-dimensional playbook that balances clinical differentiation with operational resiliency and payer-centric value demonstration. First, prioritize portfolio strategies that align innovative clinical attributes with clearly defined patient segments and care settings, ensuring that product positioning maps to real-world use cases where therapeutic advantages are most meaningful. Second, accelerate supply chain diversification and nearshoring where feasible, incorporating multi-sourcing strategies and enhanced traceability to reduce exposure to tariff volatility and single-source disruptions. Third, engage proactively with payers through outcomes-based pilots and real-world evidence initiatives that quantify comparative benefits in targeted populations and support favorable formulary placement.

Additionally, invest in enabling technologies and services that enhance adherence and simplify home administration, including patient education, remote monitoring and specialty pharmacy partnerships that streamline delivery. Cultivate cross-functional collaborations that link clinical affairs, market access and commercial teams to produce compelling value dossiers that anticipate payer scrutiny. Finally, consider disciplined M&A and alliance activity to shore up capabilities in manufacturing, digital health, and near-term pipeline assets that can accelerate time-to-market and create defensible differentiation.

By integrating these strategic elements-clinical focus, supply resilience, payer engagement and supportive services-industry leaders can reduce commercial risk, reinforce clinician trust, and expand patient access while preserving margin and long-term growth potential.

A transparent mixed-methods approach combining clinician interviews, procurement insights, regulatory review, and supply chain analysis to validate findings

The research underpinning this report combined primary qualitative inquiry with systematic secondary analysis to create a robust evidence base. Primary research included in-depth interviews with clinicians across cardiology and vascular medicine, procurement leaders from hospitals and health systems, executives from manufacturers and distributors, and subject-matter experts in regulatory affairs and supply chain logistics. These conversations were designed to capture real-world practice patterns, procurement priorities, operational constraints, and the decision criteria used by formulary committees and payers.

Secondary research involved comprehensive review of peer-reviewed clinical literature, regulatory approvals, product labeling, and public company disclosures to verify clinical attributes, safety profiles and regulatory milestones. Supply chain assessments drew on trade flow data and industry reporting to identify sourcing concentrations and recent shifts in manufacturer footprints. Findings were synthesized through cross-validation between primary insights and secondary sources, with scenario analysis employed to evaluate potential impacts of policy changes and supply disruptions. Throughout, emphasis was placed on transparency of assumptions, triangulation of evidence sources, and relevance to commercial and clinical decision-makers.

Synthesis of clinical, operational, and commercial drivers that determine access, competitive advantage, and strategic imperatives for anticoagulant stakeholders

The evolving anticoagulant landscape presents both disruption and opportunity. Clinical innovation, including oral agents and novel mechanisms under investigation, is reshaping care pathways and enabling broader outpatient management. Concurrently, shifts in site-of-care economics, the rise of digital adherence tools and increased focus on home administration are changing where and how therapies are delivered. Tariff-driven procurement pressures and supply chain realignment have introduced new operational priorities for manufacturers and health systems, underscoring the strategic importance of supply resilience and diversified sourcing.

Moving forward, the ability to couple clinical differentiation with demonstrable real-world value and reliable supply will determine winners and laggards. Stakeholders who proactively engage payers with outcomes data, invest in enabling services that support adherence and decentralization, and strengthen manufacturing footprints will be better positioned to capture clinical and commercial upside. Conversely, those who rely solely on legacy models without addressing payer expectations or supply vulnerabilities risk erosion of access and competitive displacement. In sum, success in this environment requires an integrated strategy that aligns therapeutic innovation, operational capability and market access execution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of remote patient monitoring technologies for personalized anticoagulant therapy dosing guidance
  • 5.2. Strategic collaborations between biotech startups and established pharmaceutical firms to accelerate novel factor XI inhibitor trials
  • 5.3. Emerging use of real-world evidence in regulatory submissions for novel anticoagulant approval pathways
  • 5.4. Integration of artificial intelligence algorithms to predict individual bleeding risk in anticoagulant prescribing
  • 5.5. Increasing off-label prescribing of low-dose rivaroxaban for post-operative venous thromboembolism prevention in high-risk patients
  • 5.6. Shift towards patient-centric digital adherence tools to improve direct oral anticoagulant compliance and outcomes
  • 5.7. Market entry dynamics of generic versions of factor Xa inhibitors following patent cliffs in major markets

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anticoagulants Market, by Drug Class

  • 8.1. Direct Oral Anticoagulants
  • 8.2. Low Molecular Weight Heparin
  • 8.3. Unfractionated Heparin
  • 8.4. Vitamin K Antagonists

9. Anticoagulants Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intravenous
    • 9.1.2. Subcutaneous
  • 9.2. Oral

10. Anticoagulants Market, by Indication

  • 10.1. Atrial Fibrillation
  • 10.2. Deep Vein Thrombosis
  • 10.3. Pulmonary Embolism
  • 10.4. Venous Thromboembolism Prevention

11. Anticoagulants Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Clinics
  • 11.3. Homecare Settings
  • 11.4. Hospitals

12. Anticoagulants Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online Pharmacy

13. Anticoagulants Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Anticoagulants Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Anticoagulants Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Johnson & Johnson
    • 16.3.2. Bayer AG
    • 16.3.3. Boehringer Ingelheim GmbH
    • 16.3.4. Bristol-Myers Squibb Company
    • 16.3.5. Daiichi Sankyo Company, Limited
    • 16.3.6. Sanofi S.A.
    • 16.3.7. Pfizer Inc.
    • 16.3.8. Abbott Laboratories
    • 16.3.9. Amgen Inc.
    • 16.3.10. Novartis AG
    • 16.3.11. Teva Pharmaceutical Industries Ltd.
    • 16.3.12. Dr. Reddy's Laboratories Ltd.
    • 16.3.13. Sun Pharmaceutical Industries Ltd.
    • 16.3.14. Lupin Limited
    • 16.3.15. Cipla Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTICOAGULANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTICOAGULANTS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTICOAGULANTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANTICOAGULANTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANTICOAGULANTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANTICOAGULANTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANTICOAGULANTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTICOAGULANTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTICOAGULANTS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTICOAGULANTS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTICOAGULANTS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTICOAGULANTS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTICOAGULANTS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTICOAGULANTS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTICOAGULANTS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTICOAGULANTS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTICOAGULANTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTICOAGULANTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTICOAGULANTS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTICOAGULANTS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTICOAGULANTS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTICOAGULANTS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ATRIAL FIBRILLATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ATRIAL FIBRILLATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ATRIAL FIBRILLATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ATRIAL FIBRILLATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTICOAGULANTS MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTICOAGULANTS MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTICOAGULANTS MARKET SIZE, BY PULMONARY EMBOLISM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTICOAGULANTS MARKET SIZE, BY PULMONARY EMBOLISM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTICOAGULANTS MARKET SIZE, BY PULMONARY EMBOLISM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTICOAGULANTS MARKET SIZE, BY PULMONARY EMBOLISM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTICOAGULANTS MARKET SIZE, BY VENOUS THROMBOEMBOLISM PREVENTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTICOAGULANTS MARKET SIZE, BY VENOUS THROMBOEMBOLISM PREVENTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTICOAGULANTS MARKET SIZE, BY VENOUS THROMBOEMBOLISM PREVENTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTICOAGULANTS MARKET SIZE, BY VENOUS THROMBOEMBOLISM PREVENTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTICOAGULANTS MARKET SIZE, BY VENOUS THROMBOEMBOLISM PREVENTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTICOAGULANTS MARKET SIZE, BY VENOUS THROMBOEMBOLISM PREVENTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTICOAGULANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTICOAGULANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTICOAGULANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTICOAGULANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTICOAGULANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTICOAGULANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTICOAGULANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTICOAGULANTS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTICOAGULANTS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTICOAGULANTS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTICOAGULANTS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTICOAGULANTS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTICOAGULANTS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTICOAGULANTS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTICOAGULANTS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTICOAGULANTS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTICOAGULANTS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTICOAGULANTS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTICOAGULANTS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTICOAGULANTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTICOAGULANTS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTICOAGULANTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTICOAGULANTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTICOAGULANTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTICOAGULANTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTICOAGULANTS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTICOAGULANTS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTICOAGULANTS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTICOAGULANTS MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTICOAGULANTS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTICOAGULANTS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS ANTICOAGULANTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS ANTICOAGULANTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS ANTICOAGULANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE ANTICOAGULANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 200. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. AFRICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 214. AFRICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA ANTICOAGULANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ANTICOAGULANTS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ANTICOAGULANTS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN ANTICOAGULANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. GCC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GCC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GCC ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. GCC ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. GCC ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. GCC ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. GCC ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 262. GCC ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 263. GCC ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 264. GCC ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 265. GCC ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. GCC ANTICOAGULANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. GCC ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. GCC ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. BRICS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. BRICS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. BRICS ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 286. BRICS ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 287. BRICS ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. BRICS ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS ANTICOAGULANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. G7 ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. G7 ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. G7 ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 300. G7 ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 301. G7 ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. G7 ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 303. G7 ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 304. G7 ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 305. G7 ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 306. G7 ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 307. G7 ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. G7 ANTICOAGULANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. G7 ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. G7 ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. NATO ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. NATO ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. NATO ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 314. NATO ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 315. NATO ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 316. NATO ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 317. NATO ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 318. NATO ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 319. NATO ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 320. NATO ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 321. NATO ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 322. NATO ANTICOAGULANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 323. NATO ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 324. NATO ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 325. GLOBAL ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. GLOBAL ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 329. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 331. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 333. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 335. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 336. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 337. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 338. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 339. CANADA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 340. CANADA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 341. CANADA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 342. CANADA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 343. CANADA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 344. CANADA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 345. CANADA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 346. CANADA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 347. CANADA ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 348. CANADA ANTICOAGULANTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 349. CANADA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 350. CANADA